MURANO was a randomised (1:1), multicentre, open label, phase 3 study that evaluated the efficacy and safety profile of VENCLEXTA in combination with rituximab versus bendamustine in combination with rituximab in patients with CLL who had received at least one line of prior therapy.1-3
Watch the videos below to learn more.
5-year MURANO study outcomes: VEN+R as a fixed duration R/R CLL therapy†
(<2 mins)
†VENCLEXTA must be administered according to a weekly ramp-up schedule to the daily dose of 400 mg over a period of 5 weeks. Rituximab must be administered after a patient has received VENCLEXTA 400 mg daily for 7 days. Patients should continue VENCLEXTA 400 mg once daily for up to 24 months from Cycle 1 Day 1 of rituximab in the absence of disease progression or unacceptable toxicity.3 Please read the full product information before prescribing VENCLEXTA.3
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
CLL: chronic lymphocytic leukaemia. PBS: Pharmaceutical Benefits Scheme. R/R CLL: relapsed or refractory CLL. TLS: tumour lysis syndrome.
References: 1. Kater AP et al. Five-year analysis of MURANO study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (CLL) patients (pts) following fixed duration venetoclax-rituximab (VenR) therapy (Tx). Abstract presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; 5–8 December 2020; Virtual meeting. 2. Seymour JF et al. N Engl J Med 2018; 378(12): 1107–20. 3. VENCLEXTA Product Information.
AU-VEN-200035 Last revised September 2022